Increased efficacy of sulfadoxine-pyrimethamine in the treatment of uncomplicated falciparum malaria among children with sickle cell trait in Western Kenya

Journal of Infectious Diseases

Volumn 186, Issue 11, 2002, Pages 1661-1668

  Terlouw, Dianne J ^a,b,c   Aidoo, Michael A ^a   Udhayakumar, Venkatachalam ^a   Kolczak, Margarette S ^a   Oloo, Aggrey J ^b,e   Kager, Piet A ^c   Lal, Altaf A ^a   Nahlen, Bernard L ^a,b,d   Ter Kuile, Feiko O ^a,b,c  

^a NATL CENTER FOR INFECTIOUS DISEASES   (United States)

^b KENYA MEDICAL RESEARCH INSTITUTE   (Kenya)

^c UNIVERSITY OF AMSTERDAM   (Netherlands)

^d WORLD HEALTH ORGANIZATION   (Switzerland)

^e MOI UNIVERSITY   (Kenya)

Author keywords

[No Author keywords available]

Indexed keywords

FALCIDIN; FANSIDAR; HEMOGLOBIN S; ORODAR;

ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE TRANSMISSION; DRUG EFFICACY; FEMALE; HUMAN; KENYA; MAJOR CLINICAL STUDY; MALARIA; MALE; PARASITEMIA; PARASITOLOGY; PHENOTYPE; PRESCHOOL CHILD; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SICKLE CELL TRAIT; TREATMENT FAILURE; TREATMENT OUTCOME;

ANIMALS; ANTIMALARIALS; CHILD, PRESCHOOL; DRUG COMBINATIONS; FEMALE; HEMOGLOBIN A; HEMOGLOBIN, SICKLE; HUMANS; INFANT; KENYA; MALARIA, FALCIPARUM; MALE; PARASITEMIA; PLASMODIUM FALCIPARUM; PYRIMETHAMINE; RETROSPECTIVE STUDIES; SICKLE CELL TRAIT; SULFADOXINE; TREATMENT OUTCOME;

EID: 0036891350     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/345363     Document Type: Article

References (43)

1. Hill AV, Allsopp CE, Kwiatkowski D, et al. Common West African HLA antigens are associated with protection from severe malaria. Nature 1991; 352:595-600.
2. Aidoo M, Terlouw DJ. Kolczak MS, et al. Protective effects of the sickle cell gene against malaria morbidity and mortality. Lancet 2002; 359:1311-2.
3. Greenwood B, Marsh K, Snow R. Why do some African children develop severe malaria? Parasitol Today 1991; 7:277-81.
4. White NJ, Nosten F, Looareesuwan S, et al. Averting a malaria disaster. Lancet 1999; 353:1965-7.
5. White NJ. Why is it that antimalarial drug treatments do not always work? Ann Trop Med Parasitol 1998; 92:449-58.
6. Yuthavong Y, Butthep P, Bunyaratvej A, Fucharoen S. Decreased sensitivity of artesunate and chloroquine of Plasmodium falciparum infecting hemoglobin H and/or hemoglobin constant spring erythrocytes. J Clin Invest 1989; 83:502-5.
7. Senok AC, Nelson EAS, Li K, Oppenheimer S J. Thalassaemia trait, red blood cell age and oxidant stress: Effects on Plasmodium falciparum growth and sensitivity to artemisinin. Trans R Soc Trop Med Hyg 1997; 91:585-9.
8. Mockenhaupt FP, May J, Bergqvist Y, Meyer CG, Falusi AG, Bienzle U. Evidence for a reduced effect of chloroquine against Plasmodium falciparum in alpha-thalassaemic children. Trop Med Int Health 2001; 6:102-7.
9. Nguyen-Dinh P, Parvin RM. Haemoglobin S and in vitro chloroquine susceptibility of Plasmodium falciparum. Lancet 1986; 2:1278.
10. Brandling-Bennett AD, Oloo AJ, Watkins WM, Boriga DA, Kariuki DM, Collins WE. Chloroquine treatment of falciparum malaria in an area of Kenya of intermediate chloroquine resistance. Trans R Soc Trop Med Hyg 1988; 82:833-7.
11. Bloland PB, Boriga DA, Ruebush TK, et al. Longitudinal cohort study of the epidemiology of malaria infections in an area of intense malaria transmission. II. Descriptive epidemiology of malaria infection and disease among children. Am J Trop Med Hyg 1999; 60:641-8.
12. Bloland PB, Ruebush TK, McCormick JB, et al. Longitudinal cohort study of the epidemiology of malaria infections in an area of intense malaria transmission. I. Description of study site, general methodology, and study population. Am J Trop Med Hyg 1999; 60:635-40.
13. Beier JC, Oster CN, Onyango FK, et al. Plasmodium falciparum incidence relative to entomologic inoculation rates at a site proposed for testing malaria vaccines in western Kenya. Am J Trop Med Hyg 1994; 50:529-36.
14. Shretta R, Omumbo J, Rapuoda B, Snow RW. Using evidence to change antimalarial drug policy in Kenya. Trop Med Int Health 2000; 5:755-64.
15. Severe and complicated malaria. World Health Organization, Division of Control of Tropical Diseases. Trans R Soc Trop Med Hyg 1990; 84(Suppl 2): 1-65.
16. World Health Organization. Assessment of Therapeutic Efficacy of Antimalarial Drugs for Uncomplicated Malaria in Areas with Intense Transmission [Report No. WHO/MAL/96.1077]. Geneva: WHO, 1996.
17. Behrman RE, Kliegman RM, Jenson HB, eds. Nelson Textbook of Pediatrics. 16th Ed. Philadelphia: WB Saunders, 2000.
18. Wu DY, Ugozzoli L, Pal BK, Wallace RB. Allele-specific enzymatic amplification of beta-globin genomic DNA for diagnosis of sickle cell anemia. Proc Natl Acad Sci USA 1989; 86:2757-60.
19. McCullagh P, Nelder JA. Generalized Linear Models. London: Chapman & Hall, 1989.
20. Skov T, Deddens J, Petersen MR, Endahl L. Prevalence proportion ratios: Estimation and hypothesis testing. Int J Epidemiol 1998; 27:91-5.
21. Kleinbaum DG, Kupper LL, Muller KE, Nizam A. Applied Regression Analysis and other Multivariable Methods. 3rd Ed. Belmont, CA: Duxbury Press, 1998.
22. Greenland S. Introduction to regression modeling. In: Rothman KJ, Greenland S, eds. Modern Epidemiology. 2nd Ed. Philadelphia: Lippincott-Raven, 1998:401-35.
23. Robins JM. The control of confounding by intermediate variables. Stat Med 1989; 8:679-701.
24. UN Administrative Committee on Coordination: Sub-Committee on Nutrition (ACC/SCN). Fourth Report on the World Nutrition Situation. Geneva: ACC/SCN in collaboration with International Food Policy Research Institute, 2000.
25. World Health Organization. Physical Status: The Use of and Interpretation of Anthropometry [Technical Report Series No. 854]. Geneva: WHO, 1995.
26. ter Kuile FO, Luxemburger C, Nosten F, Thwai KL, Chongsuphajaisiddhi T, White NJ. Predictors of mefloquine treatment failure: A prospective study of 1590 patients with uncomplicated falciparum malaria. Trans R Soc Trop Med Hyg 1995; 89:660-4.
27. Wolday D, Kibreab T, Bukenya D, Hodes R. Sensitivity of Plasmodium falciparum in vivo to chloroquine and pyrimethamine-sulfadoxine in Rwandan patients in a refugee camp in Zaire. Trans R Soc Trop Med Hyg 1995; 89:654-6.
28. World Health Organization. Drug Resistance in Malaria [Report No. WHO/ CDS/CSR/DRS/2001.4]. Geneva: WHO, 2001.
29. Hess FI, Nukuro E, Judson L, Rodgers J, Nothdurft HD, Rieckmann KH. Anti-malarial drug resistance, malnutrition and socio-economic status. Trop Med Int Health 1997; 2:721-8.
30. Mutabingwa T, Nzila A, Mberu E, et al. Chlorproguanil-dapsone for treatment of drug-resistant falciparum malaria in Tanzania. Lancet 2001; 358:1218-23.
31. Vattanaviboon P, Wilairat P, Yuthavong Y. Binding of dihydroartemisinin to hemoglobin H: Role in drug accumulation and host-induced antimalarial ineffectiveness of alpha-thalassemic erythrocytes. Mol Pharmacol 1998; 53:492-6.
32. Charoenteeraboon J, Kamchonwongpaisan S, Wilairat P, Vattanaviboon P, Yuthavong Y. Inactivation of artemisinin by thalassemic erythrocytes. Biochem Pharmacol 2000; 59:1337-44.
33. Orjih AU. Increased accumulation of chloroquine and desethylchloroquine in homozygous sickle cells. Bull World Health Organ 1987; 65:51-5.
34. Friedman MJ. Hemoglobin and the red cell membrane: Increased binding polymorphic hemoglobins and measurement of free radicals in the membrane. In: Brewer GJ, ed. The Red Cell. New York: Alan R Liss, 1981:519.
35. Pasvol G, Weatherall DJ, Wilson RJ. Cellular mechanism for the protective effect of haemoglobin S against P. falciparum malaria. Nature 1978; 274: 701-3.
36. Friedman MJ. Erythrocytic mechanism of sickle cell resistance to malaria. Proc Natl Acad Sci USA 1978; 75:1994-7.
37. Orjih AU, Chevli R, Fitch CD. Toxic heme in sickle cells: An explanation for death of malaria parasites. Am J Trop Med Hyg 1985; 34:223-7.
38. Luzzi GA, Merry AH, Newbold CI, Marsh K, Pasvol G, Weatherall DJ. Surface antigen expression on Plasmodium falciparum-infected erythrocytes is modified in alpha- and beta-thalassemia. J Exp Med 1991; 173:785-91.
39. Cappadoro M, Giribaldi G, O'Brien E, et al. Early phagocytosis of gfucose-6-phosphate dehydrogenase (G6PD)-deficient erythrocytes parasitized by Plasmodium falciparum may explain malaria protection in G6PD deficiency. Blood 1998; 92:2527-34.
40. Marsh K, Otoo L, Hayes RJ, Carson DC, Greenwood BM. Antibodies to blood stage antigens of Plasmodium falciparum in rural Gambians and their relation to protection against infection. Trans R Soc Trop Med Hyg 1989; 83:293-303.
41. Bayoumi RA. The sickle-cell trait modifies the intensity and specificity of the immune response against P. falciparum malaria and leads to acquired protective immunity. Med Hypotheses 1987; 22:287-98.
42. World Health Organization. Chemotherapy of Malaria and Resistance to Antimalarials [Technical Report Series No. 529]. Geneva: WHO, 1973.
43. Cravo P, Culleton R, Hunt P, Walliker D, Mackinnon MJ. Antimalarial drugs clear resistant parasites from partially immune hosts. Antimicrob Agents Chemother 2001; 45:2897-901.